Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont.
Department of Ophthalmology, Barzilai University Hospital, Ashkelon, Israel.
Can J Ophthalmol. 2018 Apr;53(2):124-130. doi: 10.1016/j.jcjo.2017.08.017. Epub 2017 Nov 27.
To compare the surgical outcomes of combined phacoemulsification with either Ahmed glaucoma valve (AGV) or Baerveldt glaucoma implant (BGI).
Retrospective cohort study.
A total of 104 eyes that underwent combined phacoemulsification with either AGV (PhacoAGV; n = 57) or BGI (PhacoBGI; n = 47) implantation.
Failure was defined as uncontrolled intraocular pressure (IOP; <5 mm Hg, ≥18 mm Hg, or <20% reduction), additional glaucoma surgery, vision-threatening complications, or progression to no-light-perception vision.
The PhacoAGV group was older (p = 0.03), had poorer baseline visual acuity (VA; p = 0.001), and had fewer previous glaucoma surgeries (p = 0.04). Both groups had similar baseline IOP (PhacoAGV: 26.4 ± 8.3 mm Hg; PhacoBGI: 25.7 ± 7.3; p = 0.66) and glaucoma medications (PhacoAGV: 3.8 ± 1.0; PhacoBGI: 3.6 ± 1.5; p = 0.54). At 2 years, failure rates were 44% in the PhacoAGV group and 23% in the PhacoBGI group (p = 0.02). Both groups had similar mean IOP reduction (PhacoAGV: 45%; PhacoBGI: 47%, p = 0.67) and medication use reduction (PhacoAGV: 47%; PhacoBGI: 58%, p = 0.38). The PhacoBGI group had higher IOP and medication use up to 1 month (p < 0.05). Both groups improved in VA from baseline (p < 0.05) and had similar overall complication rates (p = 0.31). The PhacoBGI group required more overall interventions (p < 0.0005).
This comparative study found no difference in IOP, glaucoma medications, or complication rates between PhacoAGV and PhacoBGI at 2 years, despite BGIs being implanted in patients at higher risk for failure. The PhacoAGV group had higher failure rates at 2 years. Both groups had significant improvements in VA due to removal of their cataracts. The PhacoBGI group required more interventions, but most of these were minor slit-lamp procedures.
比较白内障超声乳化联合 Ahmed 青光眼阀(AGV)或 Baerveldt 青光眼植入物(BGI)治疗的手术效果。
回顾性队列研究。
共 104 只眼接受白内障超声乳化联合 AGV(PhacoAGV;n = 57)或 BGI(PhacoBGI;n = 47)植入术。
失败定义为眼压控制不良(<5mmHg、≥18mmHg 或降低<20%)、需要额外的青光眼手术、出现威胁视力的并发症或视力进展至无光感。
PhacoAGV 组年龄较大(p = 0.03),基线视力(VA;p = 0.001)较差,且既往青光眼手术较少(p = 0.04)。两组基线眼压(PhacoAGV:26.4 ± 8.3mmHg;PhacoBGI:25.7 ± 7.3mmHg;p = 0.66)和青光眼药物使用(PhacoAGV:3.8 ± 1.0;PhacoBGI:3.6 ± 1.5;p = 0.54)相似。2 年时,PhacoAGV 组失败率为 44%,PhacoBGI 组为 23%(p = 0.02)。两组眼压平均降低率(PhacoAGV:45%;PhacoBGI:47%,p = 0.67)和药物使用减少率(PhacoAGV:47%;PhacoBGI:58%,p = 0.38)相似。PhacoBGI 组术后 1 个月内眼压和药物使用更高(p < 0.05)。两组 VA 均从基线改善(p < 0.05),总体并发症发生率相似(p = 0.31)。PhacoBGI 组需要更多的总体干预(p < 0.0005)。
尽管 BGI 植入于失败风险较高的患者,但本比较研究发现,PhacoAGV 和 PhacoBGI 在 2 年时眼压、青光眼药物或并发症发生率无差异。PhacoAGV 组 2 年时失败率较高。两组因白内障摘除均有显著的 VA 改善。PhacoBGI 组需要更多的干预,但大多数是轻微的裂隙灯检查。